

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Atogepant (Qulipta)

Notes:

- Quantity Limits: Yes

Initiation (new start) criteria, and criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-Formulary **atogepant (Qulipta)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by neurology provider **AND**
- Patient is at least 18 years old **AND**
- Prescribed for the treatment of migraine prophylaxis **AND**
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to 3 additional preventative agents for migraine, 2 of which must include: tricyclic antidepressant (amitriptyline or nortriptyline), or beta-blocker (metoprolol or propranolol), or valproate, or topiramate **AND**
- Patient has failed a trial of, or has an allergy or intolerance to fremanezumab (Ajovy), **AND** galcanezumab (Emgality) **AND** erenumab (Aimovig)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-Formulary **atogepant (Qulipta)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is at least 18 years old **AND**
- Prescribed for the treatment of migraine prophylaxis **AND**
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to 3 additional preventative agents for migraine, 2 of which must include: tricyclic antidepressant (amitriptyline or nortriptyline), or beta-blocker (metoprolol or propranolol), or valproate, or topiramate **AND**
- Patient has failed a trial of, or has an allergy or intolerance to fremanezumab (Ajovy), **AND** galcanezumab (Emgality) **AND** erenumab (Aimovig)

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Atogepant (Qulipta)

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-Formulary **atogepant (Qulipta)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a neurology provider